Frank Stenner

Frank Stenner

Auto-generated profile, based on publicly available information

Frank Stenner

Department of Oncology, University Hospital Basel, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 1995 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
USUgur Sahin
Ugur Sahin
OTO Türeci
O Türeci
HSH Schmitt
H Schmitt
BCB Cochlovius
B Cochlovius
TJT Johannes
T Johannes
MPM Pfreundschuh
M Pfreundschuh
Expression of cDNA libraries from human melanoma, renal cancer, astrocytoma, and Hodgkin disease in Escherichia coli and screening for clones reactive with high-titer IgG antibodies in autologous patient serum lead to the discovery of at least four antigens with a restricted expression pattern in each tumor. Besides antigens known to elicit T-cell responses, such as MAGE-1 and tyrosinase, numerous additional antigens that were overexpressed or specifically expressed in tumors of the same type were identified. Sequence analyses suggest that many of these molecules, besides being the target of a specific immune response, might be of relevance for tumor growth. Antibodies to a given antigen were usually confined to patients with the same tumor type. The unexpected frequency of human tumor antigens, which can be readily defined at the molecular level by the serological analysis of autologous tumor cDNA expression cloning, indicates that human neoplasms elicit multiple specific immune responses in the autologous host and provides diagnostic and therapeutic approaches to human cancer.

24 September 2018 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MSMichal A. Stanczak
Michal A. Stanczak
Shoib Sarwar SiddiquiShoib Sarwar Siddiqui
Shoib Sarwar Siddiqui
MTMarcel P. Trefny
Marcel P. Trefny
DTDaniela S. Thommen
Daniela S. Thommen
KBKayluz Frias Boligan
Kayluz Frias Boligan
HLHeinz Läubli
Heinz Läubli
First-generation immune checkpoint inhibitors, including anti–CTLA-4 and anti–programmed death 1 (anti–PD-1) antibodies, have led to major clinical progress, yet resistance frequently leads to treatment failure. Thus, new targets acting on T cells are needed. CD33-related sialic acid–binding immunoglobulin-like lectins (Siglecs) are pattern-recognition immune receptors binding to a range of sialoglycan ligands, which appear to function as self-associated molecular patterns (SAMPs) that suppress autoimmune responses. Siglecs are expressed at very low levels on normal T cells, and these receptors were not until recently considered as interesting targets on T cells for cancer immunotherapy. Here, we show an upregulation of Siglecs, including Siglec-9, on tumor-infiltrating T cells from non–small cell lung cancer (NSCLC), colorectal, and ovarian cancer patients. Siglec-9–expressing T cells coexpressed several inhibitory receptors, including PD-1. Targeting of the sialoglycan-SAMP/Siglec pathway in vitro and in vivo resulted in increased anticancer immunity. T cell expression of Siglec-9 in NSCLC patients correlated with reduced survival, and Siglec-9 polymorphisms showed association with the risk of developing lung and colorectal cancer. Our data identify the sialoglycan-SAMP/Siglec pathway as a potential target for improving T cell activation for immunotherapy.

14 November 2006 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
SBStefan Bauer
Stefan Bauer
MJMichael C Jendro
Michael C Jendro
AWAndreas Wadle
Andreas Wadle
SKSascha Kleber
Sascha Kleber
FSFrank Stenner
Frank Stenner
CRChristoph Renner
Christoph Renner
Fibroblast activation protein (FAP), as described so far, is a type II cell surface serine protease expressed by fibroblastic cells in areas of active tissue remodelling such as tumour stroma or healing wounds. We investigated the expression of FAP by fibroblast-like synoviocytes (FLSs) and compared the synovial expression pattern in rheumatoid arthritis (RA) and osteoarthritis (OA) patients. Synovial tissue from diseased joints of 20 patients, 10 patients with refractory RA and 10 patients with end-stage OA, was collected during routine surgery. As a result, FLSs from intensively inflamed synovial tissues of refractory RA expressed FAP at high density. Moreover, FAP expression was co-localised with matrix metalloproteinases (MMP-1 and MMP-13) and CD44 splice variants v3 and v7/8 known to play a major role in the concert of extracellular matrix degradation. The pattern of signals appeared to constitute a characteristic feature of FLSs involved in rheumatoid arthritic joint-destructive processes. These FAP-expressing FLSs with a phenotype of smooth muscle actin-positive myofibroblasts were located in the lining layer of the synovium and differ distinctly from Thy-1-expressing and non-proliferating fibroblasts of the articular matrix. The intensity of FAP-specific staining in synovial tissue from patients with RA was found to be different when compared with end-stage OA. Because expression of FAP by RA FLSs has not been described before, the findings of this study highlight a novel element in cartilage and bone destruction of arthritic joints. Moreover, the specific expression pattern qualifies FAP as a therapeutic target for inhibiting the destructive potential of fibroblast-like synovial cells.

1 May 2005 in Experimental Cell Research
Verified
Journal Article
Closed access
HLHeike Liewen
Heike Liewen
IMIvo Meinhold-Heerlein
Ivo Meinhold-Heerlein
VOVasco Oliveira
Vasco Oliveira
RSRobert Schwarzenbacher
Robert Schwarzenbacher
GLGuorong Luo
Guorong Luo
FSFrank Stenner-Liewen
Frank Stenner-Liewen

22 May 2018 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
HLHeinz Läubli
Heinz Läubli
CBCatharina Balmelli
Catharina Balmelli
LKLukas Kaufmann
Lukas Kaufmann
MSMichal Stanczak
Michal Stanczak
MSMohammedyaseen Syedbasha
Mohammedyaseen Syedbasha
SRSacha Rothschild
Sacha Rothschild
Background Immune checkpoint inhibiting antibodies were introduced into routine clinical practice for cancer patients. Checkpoint blockade has led to durable remissions in some patients, but may also induce immune-related adverse events (irAEs). Lung cancer patients show an increased risk for complications, when infected with influenza viruses. Therefore, vaccination is recommended. However, the efficacy and safety of influenza vaccination during checkpoint blockade and its influence on irAEs is unclear. Similarly, the influence of vaccinations on T cell-mediated immune reactions in patients during PD-1 blockade remains poorly defined. Methods We vaccinated 23 lung cancer patients and 11 age-matched healthy controls using a trivalent inactivated influenza vaccine to investigate vaccine-induced immunity and safety during checkpoint blockade. Results We did not observe significant differences between patients and healthy controls in vaccine-induced antibody titers against all three viral antigens. Influenza vaccination resulted in protective titers in more than 60% of patients/participants. In cancer patients, the post-vaccine frequency of irAEs was 52.2% with a median time to occurrence of 3.2 months after vaccination. Six of 23 patients (26.1%) showed severe grade 3/4 irAEs. This frequency of irAEs might be higher than the rate previously published in the literature and the rate observed in a non-study population at our institution (all grades 25.5%, grade 3/4 9.8%). Conclusions Although this is a non-randomized trial with a limited number of patients, the increased rate of immunological toxicity is concerning. This finding should be studied in a larger patient population.

1 July 2013 in European Urology
Verified
Journal Article
Closed access
ATArnoud J Templeton
Arnoud J Templeton
VDValérie Dutoit
Valérie Dutoit
RCRichard Cathomas
Richard Cathomas
CRChristian Rothermundt
Christian Rothermundt
DBDaniela Bärtschi
Daniela Bärtschi
SGSilke Gillessen
Silke Gillessen